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SUMMARY
The antimalarial drug mefloquine has promising antischistosomal properties killing haematophagous adult schistosomes as
well as schistosomula. Themode of action and involved drug targets ofmefloquine inSchistosomamansoni schistosomula are
unknown. In order to identify mefloquine-binding proteins and thus potential drug targets, mefloquine affinity
chromatography with S. mansoni schistosomula crude extracts was performed. We found one specific mefloquine-binding
protein that was identified by mass spectrometry as the glycolytic enzyme enolase (Q27877). Enolase activity assays were
performed on schistosomula crude extracts and on the recombinant enolase Q27877 expressed in Escherichia coli.
In schistosomula crude extracts enolase activity was inhibited by mefloquine and by the enolase inhibitor sodium fluoride,
while activity of the recombinant enolase was not affected. In contrast to enolase from crude extracts, recombinant Q27877
did not bind to mefloquine-agarose. Using isothermal microcalorimetry, we next investigated the metabolic inhibition
of mefloquine and 3 known glycolytic inhibitors in Schistosoma spp., namely sodium fluoride, 3-bromopyruvate and
menadione on schistosomula in the presence or absence of glucose. We found that in the presence of glucose, schistosomula
were less affected by mefloquine, sodium fluoride and 3-bromopyruvate, whereas glucose had no protective effect when
schistosomula had been exposed to menadione. These results suggest a potential role of mefloquine as an inhibitor of
glycolysis, at least in stages where other targets like haem degradation are not relevant.
Key words: Schistosoma mansoni, affinity chromatography, mefloquine, drug target, enolase, metabolic inhibition,
isothermal microcalorimetry, glycolysis.
INTRODUCTION
Antischistosomal chemotherapy is still restricted
to the use of praziquantel. The antimalarial drug
mefloquine, a synthetic analogue of quinine has
promising antischistosomal activity in vitro and
in vivo (Keiser et al. 2009, 2010; Xiao et al. 2011).
The mode of action and the target of mefloquine
in Schistosoma spp. are, however, not known.
Knowledge of the drug target might, however, aid
in the design and discovery of novel antischistosomal
drugs (Renslo and McKerrow, 2006; Sleno and
Emili, 2008).
There is good evidence that in Plasmodium spp.
mefloquine interferes with haemoglobin degradation.
Toxic haem is released when the parasite feeds
on haemoglobin. The haem is rapidly oxidized to
haemin and subsequently converted to haemozoin.
In the presence of mefloquine the conversion of free
haem to haemozoin is inhibited. As a consequence,
toxic haem and haemin complexes accumulate and
kill the parasite (Dorn et al. 1998; Zhang et al. 1999;
Pasternack et al. 2010).
Schistosomes feed on blood and haem is detoxified
into large insoluble crystals identical to Plasmodium
haemozoin (Oliveira et al. 2000). Therefore, a similar
mode of action of mefloquine in both parasites is
probable. A recently conducted in vitro study
suggests that mefloquine interferes with the haem
detoxification pathway in Schistosoma mansoni, since
a more pronounced activity of the drug was observed
against S. mansoni in the presence of haemin
(Manneck et al. 2011a). However, mefloquine also
shows high in vitro activities on 1-day-old S. mansoni
schistosomula and on adult schistosomes without
addition of haemin or red blood cells. In fact, RNAi
studies have shown that schistosomula show an
extensive uptake of exogenous material into the gut
immediately after transformation of cercariae into
schistosomula. Haemoglobin-derived pigment is
present in the gut of 2-day-old schistosomula, but
there is no evidence for blood uptake at earlier time-
points (Stefanic et al. 2010). This suggests that the
drug may have targets independent of haemoglobin
digestion.
The purpose of the present work was to identify
targets for mefloquine in 1-day-old, most likely
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non-haem feeding S. mansoni schistosomula. Schi-
stosomula can easily be produced by mechanical
transformation of cercariae obtained from infected
Biomphalaria glabrata snails (Keiser, 2010).
Here, we present a mefloquine affinity chromato-
graphy study (Müller et al. 2008) in order to identify
mefloquine-binding proteins in schistosomula
and report on the identification of S. mansoni enolase
(EC 4.2.1.11; Q27877) as a major mefloquine-
binding protein. Enolase is the enzyme catalysing
the conversion of phosphoglycerate to phosphoenol-
pyruvate in the Embden-Meyerhoff-Parnas pathway
of glycolysis. These investigations were complemen-
ted by functional enolase assays and by isothermal
microcalorimetry studies (Manneck et al. 2011b).
MATERIALS AND METHODS
Parasite
The S. mansoni life cycle is maintained at the
Swiss Tropical and Public Health Institute in
Basel, Switzerland. The intermediate host snails
(Biomphalaria glabrata) were exposed to light for
approximately 3 h around noon and subsequently
cercariae of S. mansoni were harvested.
Chemicals and drugs
Mefloquine hydrochloride (414·81 g/mol) was
kindly provided by Mepha Pharma AG (Aesch,
Switzerland). Penicillin/streptomycin solution and
M199 culture medium are products from Gibco/
Invitrogen (Carlsbad, USA) obtained by Lubio
Science GmbH (Lucerne, Switzerland). If not
otherwise stated, all chemical reagents were from
Sigma-AldrichChemieGmbH(Buchs,Switzerland).
Drug stock solutions were prepared in DMSO or
water and stored at −20 °C.
Preparation of S. mansoni schistosomula
Cercariae of S. mansoni were mechanically trans-
formed into schistosomula by repeat vortexing as
described previously (Keiser, 2010; Manneck et al.
2010). The schistosomula were then kept in M199
culture medium supplemented with 5% heat-
inactivated foetal calf serum and 100U/ml penicillin
and 100 μg/ml streptomycin at 37 °C in an atmosphere
of 5% CO2 for a minimum of 3–12 h, to assure
that transformation into the schistosomular stage
was completed. Afterwards the parasite suspension
was centrifuged (8000 g, 5 min, room temperature),
washed twice with phosphate-buffered saline (PBS),
and followed by another centrifugation step. The
pellet was stored at −20 °C.
Isothermal microcalorimetry
A 48-channel isothermal microcalorimeter (Model
TAM 48, TA Instruments, New Castle, Delaware,
USA) was used to measure the production of heat by
S. mansoni schistosomula incubated with 1 of 3
different glycolytic inhibitors, namely fluoride (1 and
20mM), menadione (50 μM) and 3-bromopyruvate
(0·5mM) or mefloquine (24 and 48 μM; 10 and
20mg/l). Untreated schistosomula and dead parasites
served as controls. Parasites were killed with ethanol
and death was confirmed by microscopical evaluation
as described previously (Manneck et al. 2011a). Pure
medium represented the background control. The
calorimeter and the injection system were described
in detail in a previous publication (Manneck et al.
2011b). Briefly, glass ampoules were filled with
1800 μl of culture medium M199 with or without
glucose supplementation (20 mM). Then 100 μl of
schistosomula suspension containing approximately
600 schistosomula were added. Ampoules were
placed into the measuring channels and when a stable
signal was obtained (approximately after 12 h), 100 μl
of medium containing different volumes of drug
stock solution or ofDMSO (as a solvent control) were
injected into the ampoules. Heat-flows with 1 data
point per 10min were recorded for 96 h at maximum.
Heat-flow curves of treated and untreated parasites
were examined before and after addition of drug.
Heat-production of schistosomula treated with the
compound alone or in the presence of glucose were
compared 24 h after drug addition. All samples were
analysed in triplicate.
Preparation of schistosomula crude extracts
For protein extraction, frozen schistosomula pellets
were re-suspended in ice-cold extraction buffer
consisting of PBS, 1% Triton-X-100, and a protease
inhibitor cocktail (Halt, Thermo Scientific,
Rockland, IL, USA). Suspensions were vortexed
thoroughly following repeated freezing on dry ice-
isopropanol and thawing. After 3 cycles of freezing
and thawing, the suspension was centrifuged
(15 200 g, 10 min, 4 °C). Supernatants were collected,
and extraction of pellets was repeated twice. The
supernatants were combined and subjected to enolase
assays or to mefloquine-agarose affinity chromato-
graphy. For affinity chromatography, approximately
8·5×105 parasites (10 transformation procedures
with 70–90 intermediate host snails each) were
extracted in 3×1ml of extraction buffer. For enolase
assays less parasites (about 4×105 schistosomula) and
accordingly modified extraction volumes were used.
Affinity chromatography with S. mansoni
schistosomula crude extracts on mefloquine-epoxy
agarose
In order to produce mefloquine-agarose, 0·3 g lyo-
philized epoxy-agarose with a C-12-spacer was
suspended in 15ml of H2O and centrifuged at 300 g
for 5 min. Washes in water were repeated twice, and
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the suspension was washed once in coupling buffer
(NaHCO3 0·1M, pH 9·5). After the last wash, epoxy-
agarose was suspended in 2ml of coupling buffer.
Twenty mg mefloquine were dissolved in 2ml of
dimethyl-formamide and added to the agarose. The
mixture was incubated for 3 days at 37 °C under slow
but continuous shaking in order to allow coupling of
the epoxy group to mefloquine via the OH- group of
the piperidine-2-yl-methanol part of the molecule.
For the negative control a mock columnwas prepared
by blocking a column with ethanol-amine only
(Müller et al. 2008). Prior to the runs, both columns
(bed volumes ca. 1 ml each) were combined in
a tandem (mock column first, then mefloquine
column) and washed with 50ml of PBS equilibrated
at 20 °C. Then 3ml of schistosomula crude extract
was loaded onto the column tandem at a flow rate of
0·25ml/min. The columns were washed with PBS
until a flat baseline was detected (more than 10
column volumes). The columns were separated, and
proteins binding to the columns were eluted with
1mM mefloquine in PBS followed by elution with a
pH shift (glycine Cl− 100mM, pH 2·9) in order to
remove non-specifically bound proteins. Moreover,
fractions were taken before elution with mefloquine
(pre-mefloquine) and following a pH shift (pre-pH
shift). Sizes of these fractions ranged between 3 and
5ml. Aliquots from each fraction (200 μl) and from
the crude extract (50 μl) were taken and analysed by
SDS-PAGE. SDS-PAGE and silver staining were
performed as summarized in a recent publication
(Müller et al. 2008).
The protein identified in the mefloquine eluate
only was then further analysed bymass spectrometry.
For protein sequencing by mass spectrometry,
protein was prepared (Müller et al. 2008) and
sequenced by the Proteomics Core Facility, Faculty
of Medicine, University of Geneva, Switzerland.
Cloning and heterologous expression of recombinant
S. mansoni enolase
Cloning, heterologous expression and His-tag purifi-
cation of recombinant enolase were carried out as
described (Müller et al. 2008). Briefly, in order to
clone enolase into the His-tag-expression vector
pET151 directional TOPO (Invitrogen, Carlsbad,
CA), the primers pENOfor (CACCATGTCCAT-
TTTAACGATCCAC) and pENOrev (TTATA-
CTTTGGGATGGCGGAAG) were created for
the amplification of a 1260 base pair product
encoding the enolase (Q27877) polypeptide with 4
additional bases at the 5′end allowing directional
cloning (MWG Biotech, Ebersberg, Germany).
cDNA was created from adult S. mansoni following
a protocol by Lochmatter et al. (2009) and PCR was
performed using Phusion Polymerase and the ap-
propriate protocol (Phusion TM DNA Polymerase,
High Fidelity PCR KIT, Finnzymes). The resulting
product was cloned into pET151 TOPO vector and
transformed into E. coli TOP 10 cells (Invitrogen).
Heterologous expression of enolase in positive
transformants of Escherichia coli (BL21 Star)
and subsequent his-tag purification of recombinant
enolase was performed as previously described
(Müller et al. 2008). Purified protein was stored in
50% glycerol at −20 °C.
Enolase assay
Enolase activity was determined using an enzymatic
assay coupled to pyruvate kinase and L-lactate
dehydrogenase by measuring the conversion of
NADH to NAD by the latter enzyme according to
a protocol of Sigma-Aldrich. The assay was per-
formed in a 96-well-plate containing a total volume of
250 μl in each well and 80mM triethanolamine buffer
(pH 7·4), 0·12mM ß-NADH, 25mM magnesium
sulfate, 100mM potassium chloride solution,
1·3 mM ADP, 7U/ml pyruvate kinase, 10U/ml of
lactate dehydrogenase and enolase (crude extracts or
recombinant, 2–5 μl). The reaction was initiated
by adding the enolase substrate 2-phosphoglycerate
(0–1·8 mM). Blanks without enolase and blanks
without substrate served as controls.
For inhibition studies, mefloquine and sodium
fluoride were added as indicated in Fig. 3 of the
results section (24–240 μM). All samples were
assessed in triplicate. The decrease of absorbance
of NADH was recorded for 20min at 340 nm
by continuous photometric rate determination
(VersaMax™ Absorbance Microplate Reader,
Molecular Devices, Sunnyvale, California, USA).
Effects of mefloquine on pyruvate kinase and lactate
dehydrogenase were monitored by adding phospho-
enolpyruvate (final concentration of 1·8 mM) instead
of enolase and 2-phosphoglycerate to the reaction
mix.
Statistics
Pairwise t-tests were performed using the StatsDirect
statistical software package (version 2.7.2.,
StatsDirect Ltd; Cheshire, UK). Km and Vmax values
were determined after regression analysis by the
corresponding software tool contained in the Excel
software package (Microsoft, Seattle, Washington,
USA).
RESULTS
Enolase is a major mefloquine-binding protein in
S. mansoni schistosomula
Since mefloquine was found to affect the non-
haematophagous schistosomula (Manneck et al.
2010) we aimed to identify the cellular target of this
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drug in schistosomula. Mefloquine was coupled to
epoxy-agarose, a mock-column was prepared, and
affinity chromatography was performed with schis-
tosomula crude extracts on both columns mounted in
tandem. Both columns were washed and separately
eluted with mefloquine or a low-pH buffer. The
elution with low pH of both columns yielded
bands of ca. 40 and 30 kDa. These bands were also
present to various extents in mefloquine elutions.
In addition, only elution with mefloquine of the
mefloquine-column yielded a band of ca. 50 kDa
(Fig. 1A, rectangle). This band was subjected to mass
spectrometry analysis. Eight peptides aligned with
100% protein probability to S. mansoni enolase
Q27877 (identical to AAC46884, AAC46886,
CBN61518.1) and to S. mansoni enolase C4Q3S7
(identical to XP_002573848.1, CAZ30081.1) with
23% coverage of the sequence (Fig. 1B). C4Q3S7
differed in 2 amino acids only from Q27877, namely
an isoleucine instead of a threonine in position 52 and
a phenylalanine instead of a tyrosine in position 93.
Q27877 was identified through an analysis of trans-
spliced mRNAs (Davis et al. 1995), C4Q3S7 via the
genomic sequencing effort (Berriman et al. 2009).
Analysis by BLAST (Altschul et al. 1997) revealed
that the coding sequences for both proteins were
identical (data not shown). One peptide aligned
also to enolases from S. japonicum (P33676) and
F. hepatica (Q27655), 3 aligned with the S. japonicum
enolase only, 4 were unique to S. mansoni. The
protein with the highest similarity in humans is
alpha-enolase (P06733; Fig. 1B).
Enolase activity from schistosomula crude extract is
inhibited by mefloquine
Enolase activity in parasite crude extracts was
inhibited by mefloquine in a concentration-
dependent manner at 24 μM and above. At 240 μM,
both mefloquine and sodium fluoride, a well-known
enolase inhibitor (Warburg and Christian, 1941),
nearly completely inhibited enolase activity in crude
extracts (Fig. 2). The inhibition by mefloquine was
not due to inhibition effects on the coupled reactions
catalysed by pyruvate kinase and lactate dehydro-
genase. This was shown by control assays where the
product of the reaction catalysed by enolase, namely
Fig. 1. (A) SDS-PAGE of affinity chromatography eluates of Schistosoma mansoni schistosomula extracts. Eluates were
obtained by mefloquine-agarose affinity chromatography (MQ-column; lanes 1–4) and by an ethanolamine coupled
mock column (negative control; lanes 5–8). Marker (M), crude extract (CE), Wash plus pre-mefloquine (1 and 5),
eluates with 1mM mefloquine (2 and 6 and 3 and 7), pH-shift with 0·1 M glycine at pH 2·9 (4 and 8). Bands were
visualized by silver staining. (B) Protein sequence of S. mansoni enolase Q27877 (SCHMA) and alignment with other
enolases, namely P33676 from S. japonicum (SCHJA), Q27655 from Fasciola hepatica (FASHE) and P06733 from
human (HUMAN). Peptides identified by mass spectrometry are highlighted in grey.
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phosphoenol-pyruvate, was added to the reactionmix
instead of enolase and the substrate 2-phosphoglyce-
rate. Activities of the coupled reactions performed
without mefloquine (Control, 60·6 ΔmA340/min
±3·5) or with 240 μM mefloquine (59·3ΔmA340/min
±4·6) were identical.
Subsequently, Q27877 was over-expressed as a
His-Tag protein in E. coli and affinity purified under
non-denaturing conditions (Fig. 3A). The recombi-
nant protein had enolase activity, but was not
inhibited, either by fluoride or by mefloquine at
240 μM (Fig. 3B). In order to see whether the
recombinant enzyme had the same catalytic proper-
ties as the enolase activity in crude extracts, we
performed enolase assays with both enzymes at
various substrate concentrations and determined
Km and Vmax values according to Lineweaver-
Burke. Enolase from crude extracts had nearly
1 magnitude higher Km and about 5 times lower
Vmax values than the recombinant enzyme (Table 1).
Moreover, we performed a pull-down assay on
mefloquine agarose with the recombinant enolase.
The protein was detected quantitatively in the flow-
through, hence the recombinant protein did not bind
to the column (Fig. 3C).
Glucose interferes with the antischistosomal activity
of mefloquine
Based on previously published results on metabolic
inhibition of schistosomula by mefloquine, we
compared the effect of mefloquine to compounds
well known for interfering with glycolysis, namely
sodium fluoride (Warburg and Christian, 1941) and
3-bromopyruvate (Pelicano et al. 2006).We hypothe-
sized that a supplementation of the medium
with glucose may counteract inhibition by these
compounds. Additional glucose would offer more
substrate for each reaction during glycolysis, increase
the rate of glycolysis and might decrease the
inhibitory effect of the tested glycolytic inhibitors
and of mefloquine. As a control, we included
menadione (Bueding, 1950) interfering with glycoly-
sis via induction of oxidative stress (Verrax et al.
2006).
Figure 4 illustrates the relative heat production
(metabolic activity of untreated control worms in the
absence of glucose was set to 100%) of schistosomula
incubated with the 4 tested compounds in the
presence or absence of glucose (0 and 20mM) 24 h
post-incubation. The addition of glucose caused no
significant increase as compared to the control group.
After incubation with 24 μM mefloquine in glucose-
free medium, metabolic activity of schistosomula
dropped to nearly one fifth of the control values.
Schistosomula incubated with 20mM glucose
showed a significantly higher metabolic activity
after exposure to mefloquine as compared to schisto-
somula incubated in plain medium. The same effect
was seen for schistosomula incubated with 48 μM
mefloquine. By 24 h post-incubation, metabolic
activity of parasites incubated in glucose-free med-
ium had decreased to less than 20% compared to
control values, whereas worms exposed to meflo-
quine incubated in medium containing glucose had a
significantly higher activity. When schistosomula
were incubated with a lower concentration of
10mM glucose (data not shown) again a significantly
higher heat-flow after exposure to mefloquine was
seen, when compared to schistosomula incubated
in medium without glucose. The effects of higher
mefloquine concentrations could not be evaluated
since these doses resulted in a rapid decrease of
metabolic activity of schistosomula, which was too
fast to be recordable by our system (Manneck et al.
2011b).
The addition of sodium fluoride caused a
concentration-dependent decrease of the heat-flow.
Incubation with 20mM sodium fluoride resulted in
death of all schistosomula. In the presence of 20mM
sodium fluoride plus glucose metabolic activity was
still detectable. Both parasites incubated with and
without additional glucose had similar metabolic
activities 24 h after incubation with 50 μM 3-
bromopyruvate (data not shown). In the presence
of 0·5 mM 3-bromopyruvate metabolic activity was
nearly at background levels. In the presence of
glucose and 0·5 mM 3-bromopyruvate metabolic
activity was detectable at nearly 10% of the control
levels. Finally, menadione (50 μM) killed schistoso-
mula 24 h post-incubation regardless of glucose
supplementation.
DISCUSSION
Isothermal microcalorimetry, which measures the
heat produced by microorganisms has proven to be a
Fig. 2. Mefloquine inhibits enolase activity in
Schistosoma mansoni crude extracts. Enolase assays were
performed with S. mansoni schistosomula crude extracts
in the presence of different concentrations of mefloquine
(MQ 0–240 μM) or sodium fluoride as a positive control
for inhibition (NaF 240 μM). Data are expressed as the
decrease of absorption at 340 nm over time.
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suitable method to evaluate the activity of antischis-
tosomal compounds (Manneck et al. 2011b). Energy
acquisition in schistosomes is provided mainly via
glycolysis (Bueding, 1950; Van den Bossche, 1985;
Yang et al. 2010). Compounds interfering with
glycolysis thus rapidly block muscular contraction
and heat development. We have investigated a series
of compounds directly interfering with glycolysis,
namely sodium fluoride, 3-bromopyruvate, and
menadione on schistosomula using micro-
calorimetry. Sodium fluoride is a well-characterized
inhibitor of enolase, the enzyme catalysing the
A
B
C
Fig. 3. Recombinant enolase Q27877 is not inhibited either by fluoride or by mefloquine. (A) SDS-PAGE of his-tag
purified recombinant enolase. Marker (M), crude extract (CE), flow through (FT), eluates (1–3). (B) Enolase activity
of recombinant Q27877 in the presence of 240 μM mefloquine (MQ 240) or 240 μM sodium fluoride (NaF 240).
(C) SDS-PAGE of mefloquine agarose affinity chromatography of recombinant enolase Q27877. Crude extract (CE),
flow-through (1), wash (2), pre-mefloquine (3), mefloquine (4), mefloquine pre pH-shift (5), pH-shift (0·1M glycine,
pH 2·9) (6). Bands were visualized by silver staining.
Table 1. Kinetic parameters of enolase activity
from Schistosoma mansoni schistosomula crude
extracts and of recombinant enolase Q27877
(To determine Km and Vmax values, enolase reactions were
performed with substrate concentrations ranging from 0·1
to 1·8 mM.The reciprocals of the resulting reaction rate (vi)
values and the substrate concentrations were plotted and
Km and Vmax values and the corresponding errors were
calculated by regression analysis.)
Parameter Crude extract Recombinant
Km (mM) 3·22±0·21 0·21±0·05
Vmax (mkat/mg prot) 95·2±26·2 485·2±81·5 Fig. 4. Heat-flow of Schistosoma mansoni schistosomula
24 h post-incubation with 24 μM (MQ 24) and 48 μM
mefloquine (MQ 48), 1 mM or 20mM sodium fluoride
(NaF 1, NaF 20), 0·5 mM 3-bromopyruvate (3-BP),
or with 50 μM menadione (Men) in the absence of
glucose (Control) or with glucose (20mM Glc). Mean
values±S.E. are indicated for 4 replicates. Values with
significant differences (t-tests; P< 0·05) between samples
with and without additional glucose are labelled with
asterisks.
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conversion of phosphoglycerate to phosphopyruvate
(Warburg and Christian, 1941). However, sodium
fluoride is not selective to enolase and inhibits a
variety of other enzymes such as phosphatases or
ATPases. Therefore, the reduction of glucose con-
sumption in schistosomula may also be due to effects
of sodium fluoride on other metabolic pathways.
In adult schistosomes, sodium fluoride reduces the
consumption of glucose and the production of lactate
(Bueding, 1950). Menadione is a naphthoquinone
with structural similarities to mefloquine. Similar to
sodium fluoride, it reduces glucose consumption and
lactate production in adult schistosomes (Bueding,
1950), but most likely not by an inhibition of
glycolysis but instead by an induction of oxidative
stress (Verrax et al. 2006). 3-bromopyruvate inhibits
hexokinase in the glycolytic pathway and decreases
the ATP content in cells by inhibition of ATP
production and depletion of cellular ATP. Due to its
cytotoxic activity against cancer cells, pre-clinical
trials have been launched to confirm its activity
for anticancer treatment (Pelicano et al. 2006). To
our knowledge, the antischistosomal activity of
3-bromopyruvate has not been described so far.
Our microcalorimetric studies reveal that simul-
taneous addition of glucose attenuates the metabolic
inhibition by sodium fluoride, 3-bromopyruvate and
mefloquine, but not by menadione. Note that, in the
case of sodium fluoride, the effective concentration is
very high (above 1mM), which is most likely due to a
reduced uptake of this compound by schistosomula.
This phenomenon has also been described for adult
schistosomes with at least 20mM sodium fluoride
being necessary to inhibit glucose utilization in
the parasites by 50% (Bueding, 1950). Our findings
suggest that mefloquine directly interferes with
glycolysis similar to the two inhibitors of glycolytic
enzymes rather than acting indirectly as menadione.
This assumption is corroborated by biochemical
data.
Using affinity chromatography followed by mass
spectrometry, we have identified the glycolytic
enzyme enolase as a major mefloquine-binding
protein in S. mansoni schistosomula. Enolase activity
in schistosomula crude extracts is inhibited by
mefloquine in a similar concentration range as by
sodium fluoride. The recombinant enolase Q27877
is, however, not inhibited by either mefloquine or
sodium fluoride. Moreover, the recombinant enolase
has different kinetic parameters from the activity in
crude extracts.
At first glance, these results suggest that meflo-
quine may inhibit an enolase isoform other than
our recombinant Q27877. Mammals have 3 enolase
isoforms, alpha, beta and gamma with multiple
functions beside glycolysis (Pancholi, 2001) and for
S. mansoni to date 2 isoforms of enolase, namely
Q27877 and C4Q3S7, are listed in genomic data-
bases. However, although these 2 isoforms are
provided in genomic databases, it is likely that
enolases other than Q27877 do not exist in
S. mansoni. The small differences between Q27877
and C4Q3S7, the protein derived from the genomic
sequencing effort, are most likely due to errors,
because the corresponding coding sequences are
identical. A BLAST analysis showed that Q27877
Fig. 5. Scheme summarizing glycolysis in Schistosoma and targets for inhibitors (in rectangles) as used in the present
study. A structural formula of mefloquine is shown.
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has 75% identity to human alpha-enolase, 72% to
beta-enolase, and 71% to gamma-enolase and may
thus fulfil – to a certain extent – the functional re-
quirements for all classes in mammals.
More likely, enolase from crude extracts has been
subjected to post-translational modifications and/or
interacted with other proteins present in its natural
cellular environment resulting in catalytic properties
differing from the recombinant enzyme. For example,
in mammalian cells such as human muscle fibres,
enolases may be phosphorylated (Hojlund et al.
2009). The functional implication of this phos-
phorylation is unknown so far. In yeast, enolase is
bound to vacuoles (Decker and Wickner, 2006) and
may be part of a large macromolecular complex
associated with mitochondria (Brandina et al. 2006).
In Plasmodium, enolase has been described to have
undergone post-translational modifications that are
associated to different subcellular fractions (Pal-
Bhowmick et al. 2007). Taken together, these results
indicate that a native enolase may be different from
the recombinant enolase produced in E. coli. Results
obtained with the latter may thus not reflect the
original situation.
Moreover, there is increasing evidence that in
S. bovis (Ramajo-Hernandez et al. 2007) and
S. japonicum (Yang et al. 2010) enolase is localized
not only intracellularly but also at the cell surface.
The role of this localization is unclear, but extra-
cellular enolase may be involved in the interaction
with host proteins such as plasminogen or the
immune system (Pancholi, 2001). It is possible that
an extracellular, extensively modified enolase is the
target for mefloquine. In S. japonicum, enolase is
expressed in all developmental stages, but has higher
expression levels in schistosomula than in adult
worms suggesting that enolase is critical for growth,
migration and adaption of the young schistosomes
(Yang et al. 2010).
Overall, our results suggest, that in S. mansoni
schistosomula, mefloquine inhibits enolase resulting
in an interference with glycolysis and/or in debilitat-
ing the parasite via an unknown mechanism in the
case of extracellular enolase. Since mefloquine has
3 fluorine residues, it is possible that it blocks enolase
at the same site as fluoride ions as suggested in the
scheme presented in Fig. 5. Fluoride forms a complex
with magnesium and phosphate at the active site
(Bunick and Kashket, 1982; Qin et al. 2006). There
is, however, a non-deniable discrepancy between
the concentrations of mefloquine inhibiting enolase
activity in crude extracts and the nearly 1 magnitude
lower concentrations needed for metabolic inhibition
measured by microcalorimetry and by drug sensi-
tivity assays (Manneck et al. 2011b). This suggests the
existence of other molecular targets for mefloquine.
Further work should focus on this aspect as well as on
the role of enolase in themode of action ofmefloquine
in Schistosoma spp.
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